aktive
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.smarteranalyst.com/brief/maxim-group-maintains-a-buy-rating-on-actinium-pharmaceuticals-atnm/
https://www.smarteranalyst.com/brief/oppenheimer-maintains-their-buy-rating-on-actinium-pharmaceuticals-atnm/
https://www.marketwatch.com/press-release/actinium-pharmaceuticals-inc-atnm-us-opening-the-door-to-transplant-therapy-2018-08-16
NEWS - Actinium Pharmaceuticals Inc (ATNM-US): Opening the door to transplant therapy
Published: Aug 16, 2018 5:30 a.m. ET
Maxim Group Maintains a Buy Rating on Actinium Pharmaceuticals (ATNM)
Jason Carr-August 14, 2018, 7:55 PM EDTSHARE ON:
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $3. The company’s shares opened today at $0.62.
McCarthy observed:
“Actinium announced that the Data Monitoring Committee (DMC) unanimously voted to recommend the Phase 3 SIERRA trial of Iomab-B to continue as planned. The interim safety look occurred at the 25% enrollment mark. The company will host a conference call Wednesday/tomorrow at 9am ET.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.6% and a 42.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $4.25.
NEWS - Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
Published: Aug 14, 2018 4:05 p.m. ET
NEW YORK, Aug. 14, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (nyse american:ATNM) ("Actinium" or "the Company"), today announced that it will conduct a conference call on Wednesday, August 15, 2018 at 9:00 AM ET to provide an update on the Pivotal Phase 3 SIERRA Trial (Study of Iomab-B in Elderly Relapsed/Refractory AML) of Iomab-B. Actinium recently announced that the SIERRA trial had reached twenty-five percent patient enrollment and that the independent Data Monitoring Committee (DMC) would conduct a formal analysis, which has now occurred. Post this event, members of Actinium's management team are hosting this call to provide an update on the SIERRA trial.
Conference Call Details
Date: Wednesday, August 15, 2018
Time: 9:00 AM ET
Registration Link: https://onecast.thinkpragmatic.com/ses/HKwlrC68IHB_UiNbwrpb4w~~
Toll-Free Dial-in: (855) 427-0225
Dial-in: (718) 865-8336
Conference ID: 4831
"Based on the DMC's unanimous recommendation, we are pleased that the ongoing SIERRA trial will continue as planned," said Dr. Mark Berger, Chief Medical Officer of Actinium. "This is an important milestone for Iomab-B since it is the first formal safety evaluation of the trial. We note that no Iomab-B safety concerns were raised. With new insights from the data available from the trial thus far as well as feedback from the trial sites, we will make certain protocol revisions to further expand salvage regimens in the control arm. We'll also be making it easier for patients on the Conventional Care arm who have disease progression to access Iomab-B treatment. In addition, we will be simplifying certain data collection requirements. These improvements coupled with our deeper understanding of referral patterns and other outreach efforts, are anticipated to enable the recently strengthened SIERRA clinical team to complete the trial as quickly as possible with the goal of bringing Iomab-B to a patient population with a significant unmet need."
Sandesh Seth, Actinium's Chairman and CEO added, "Iomab-B is a very compelling drug candidate that has been studied in over 500 patients in multiple hematologic malignancies including AML, myelodysplastic syndrome, lymphoma and multiple myeloma and is intended to facilitate a potentially curative bone marrow transplant. Iomab-B was developed by the Fred Hutchinson Cancer Research Center in collaboration with the National Cancer Institute and has been studied extensively by leading bone marrow transplant physicians. We are incredibly proud of the pedigree of Iomab-B and motivated by its potential to address unmet medical needs as a targeted conditioning agent in multiple hematologic diseases. We believe that Iomab-B via the SIERRA trial can be the linchpin for developing the leading franchise in targeted conditioning with an emphasis on improving bone marrow transplant access and outcomes."
About Iomab-B
Iomab-B, Actinium's lead targeted conditioning product candidate, is currently being studied in a 150-patient, multicenter pivotal Phase 3 clinical trial in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. This pivotal Phase 3 study is called the SIERRA Trial (Study of Iomab-B in Elderly Relapsed/Refractory AML). Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant which is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders. Iomab-B targets cells that express CD45, an antigen widely expressed in the hematopoietic system on all leukemic and lymphomic (white blood cells), bone marrow cells and cancer stem cells with the monoclonal antibody, BC8 or apamistamab, labeled with the radioisotope, iodine-131. By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects that conventional treatments such as chemotherapy and radiation has on most healthy tissues while effectively killing the patient's cancer and marrow cells potentially enabling more bone marrow transplants with better outcomes through targeted conditioning. In a Phase 2 clinical study in 68 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, who typically would not be transplant candidates, were able to receive a transplant after being conditioned with Iomab-B and the study resulted in significantly improved transplant success and survival. Iomab-B was developed at the Fred Hutchinson Cancer Research Center where it has been studied in almost 500 patients in a number of Phase 1 and Phase 2 clinical trials across a variety of blood cancer indications with promising results. The studies included patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). Iomab-B has been granted Orphan Drug Designation for relapsed or refractory AML in patients 55 and above by the U.S. Food and Drug Administration and the European Medicines Agency.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. The Company's targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.
Iomab-B, Actinium's lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older. Actinium's pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.
More information is available at www.actiniumpharma.com and our Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc. Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
Investor Relations
Marek Ciszewski, J.D.
949.574.3860
ATNM@liolios.com
View original content with multimedia:http://www.prnewswire.com/news-releases/actinium-to-provide-update-on-pivotal-phase-3-sierra-trial-following-positive-data-monitoring-committee-meeting-300697086.html
SOURCE Actinium Pharmaceuticals, Inc.
Copyright (C) 2018 PR Newswire. All rights reserved
Replay to an erlier post from me. Seems I'm not right about my prediction. Maybe later this month? LOL Long and strong
BTW average for my buy is 0.63
i took the oppurtunuty to add 16k Shares. Now it's time to turn north, LOL
No, no news out there. I'm a bit surprised as well about this 16% drop. From tecnical aspect the worst is over. Let Change to grow mode again. notlol
Replay to an erlier post from me. Seems I'm right. Now it would be nice to see ATNM by $1.30 middle of august. LOL and IMHO
MORE NEWS - The CEO of Actinium Pharmaceuticals (ATNM) is Buying Shares
Catie Powers-July 17, 2018, 5:30 PM EDTSHARE ON:
Today, the CEO of Actinium Pharmaceuticals (NYSE: ATNM), Sandesh Seth, bought shares of ATNM for $7,900.
This recent transaction increases Sandesh Seth’s holding in the company by 7.5% to a total of $113.4K.
See today’s analyst top recommended stocks >>
Currently, Actinium Pharmaceuticals has an average volume of 3.51M.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $4.25, reflecting a -82.0% downside. Starting in November 2015, ATNM received 45 Buy ratings in a row. Seven different firms, including B.Riley FBR and Canaccord Genuity, currently also have a Buy rating on the stock.
The insider sentiment on Actinium Pharmaceuticals has been positive according to 11 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
Incredible momentum,... another great day here in ATNM world
and again,... another great day here in ATNM world
NEWS - Actinium Pharmaceuticals (ATNM) Updates On Actimab-A MRD (Clinical trial for Minimal Residual Disease in Postremission AML Patients) - Slideshow
Jul. 11, 2018 1:42 PM ET | About: Actinium Pharmaceuticals, Inc. (ATNM)
insert-text-here
looks so, but for me even a reason to add some more
Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients
Jul. 9, 2018 at 4:14 p.m. ET on GlobeNewswire
another great day here in ATNM world
Yes a good sign, would be nice to see ATNM in the .80-is again by middle of July. Would give some confidence into the future.
researcher59 - Keep up the good work and information
Its realy silent here. Was once a great place to be and meet and discuss with some nice people. Oh by the way --> this is post no 18'000
Mon Mar 12 08:00:12 2018 EDT
Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”)
Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”)
Further development of Sollpura to be discontinued
Anthera to evaluate all strategic alternatives
Anthera to host teleconference today at 8:30 am ET
HAYWARD, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) announced today that Sollpura did not meet the non-inferiority margin of the CFA primary endpoint in the RESULT Phase 3 clinical study of exocrine pancreatic insufficiency (“EPI”) due to cystic fibrosis.
The design of the RESULT study was based on the outcome of the previous Phase 3 SOLUTION study and included a higher starting dose and more aggressive dose optimizations based on clinical signs and symptoms of malabsorption. In the RESULT study, all patients randomized to Sollpura received a starting dose that was approximately 25% higher than their pre-study porcine pancreatic enzyme replacement therapy (“PERT”) dose and 59% of subjects received further dose adjustments, yielding a mean Sollpura dose (8,673 [range 2,925 – 14,941 lipase units/kg/day]) that was both substantially higher than the comparator Pancreaze mean dose (6527 [range 2358 - 10253 units/kg/day]) and higher than the Sollpura dose in the previous SOLUTION study (mean dose of 7,286 [range 4478 - 10000 units/kg/day]). Although a proportion of patients randomized to Sollpura maintained or improved their CFA from baseline, a higher proportion of patients experienced a worsening. The mean treatment difference in CFA change from baseline was 14.3%, with upper and lower 95% confidence intervals of -18.22 and -10.39. In contrast, the treatment difference in CNA change from baseline (-1.53%) was well within the 15% non-inferiority margin. In comparison to the earlier SOLUTION study, the presence or absence of concomitant gastric acid suppressants had no meaningful effect on CFA (mean changes from baseline in CFA of -15.06% and -16.58%, respectively).
“We are greatly disappointed by the findings of the RESULT study,” shared Craig Thompson , President & CEO. “We would like to extend our deepest gratitude to the patients and their families, study investigators, and the cystic fibrosis community for the support they have provided in the clinical development of Sollpura.”
Anthera Pharmaceuticals, Inc. plans to evaluate the full data outputs and will suspend further clinical development of Sollpura, including the 20-Week Extension Period of RESULT, the SIMPLICITY study in patients ages 28 days to <7 years which was designed to assess Sollpura powder for oral solution, and the EASY study which was designed to follow the long-term safety of patients on Sollpura. In addition, Anthera Pharmaceuticals, Inc. plans to evaluate all strategic alternatives in order to maximize shareholder value.
Conference Call Details
Thank you. The estimate is a bit deep into.... For me these numbers are way to high. So i'm carefully watching,...
Any guess about tomorrows storage report? TIA
No clue about weather impact from this,...
https://nowcoast
Thanks budmgd, just unbelievable,...
But for what reason? Cannot find anything. Living in switzerland. Shame on CS
Now @ 5.50. Autsch
sh - all ok with you? Any news on xiv?
about a loss of 15%, WOW
half a dollar
pre rollover price of course, i know
February @ 3.631
Interesting february NG price,...
Natural Gas Mar '18 (NGH18)
sh, that meeans in your mind that DGAZ will go north middle of next week? Changin direction to the positive? As stated yesterday, I'm all in. TIA
all in, I believe that this is the right point now. Will see it monday
Baker-Hughes Rig Count
Released On 1/12/2018 1:00:00 PM For wk1/12, 2018
Prior Actual
N. Amer. Rig Count 1098 1215
U.S. 924 939
Gulf of Mexico 17 19
Canada 174 276
Highlights
The Baker Hughes North American rig count is up 117 rigs in the January 12 week to 1,215, led again by the rebounding volatile count for Canada following a seasonal weather-related plunge at year end. The U.S. rig count is up 15 rigs from last week to 939 and is up 280 rigs from last year at this time. The Canadian count is up 102 rigs from last week to 276 but is down 39 rigs compared to last year.
For the U.S. count, rigs classified as drilling for oil are up 10 at 752 and gas rigs are up 5 at 187. For the Canadian count, oil rigs are up 87 at 185 and gas rigs are up 15 at 91.
Rising oil prices, currently at 3-year highs and around $64 per barrel, are likely to lead to further gains in drilling activity by North American exploration and development companies.
Definition
The Baker Hughes North American rig count tracks weekly changes in the number of active operating oil & gas rigs. Used for drilling wellbores for wells that may eventually produce oil or gas, active rigs are essential for the exploration and development of oil and gas fields. Rigs that are not active are not counted. Components in the data are the United States and Canada with a separate count for the Gulf of Mexico (which is a subset of the U.S. total). The count includes only rigs that are significant users of oilfield services and supplies. Why Investors Care
bought one third of the planned position
LOL @ you sh.
But timing for going into D is like a lottery play this time. Sold all UGAZ today for a nice gain after waiting almost 5 weeks. Totaly false timing.
Would like to make it better on DGAZ this time.
Happy new year to all of you. Hope for a prosper world in 2018